For decades, the standard treatment for these potentially ... benralizumab could become the first new therapy approved for eosinophilic exacerbations of asthma and COPD in over 50 years.
Scientists have found a new treatment for people with asthma and chronic obstructive pulmonary disease (COPD) that may be more effective than current options. Over the past 50 years, treatment options ...
Scientists at Newcastle University have developed a new lung scanning method that reveals the real-time effects on lung ...
The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following promising clinical trial data.
New imaging techniques reveal real-time lung function improvements, offering a breakthrough in diagnosing and treating ...
New Study Shows Promising Results for COPD Treatment Nov. 20, 2024 — A new study shows that a form of vitamin B3 can reduce lung inflammation in COPD patients. The researchers hope it will pave ...
New Study Shows Promising Results for COPD Treatment Nov. 20, 2024 — A new study shows that a form of vitamin B3 can reduce lung inflammation in COPD patients. The researchers hope it will pave ...
But an existing injectable drug might make these attacks much less frightening, a new clinical ... of treatment, four times fewer people taking benralizumab had suffered an asthma or COPD attack ...
"But it's appalling that this is the first new treatment for those suffering from asthma and COPD attacks in 50 years, indicating how desperately underfunded lung health research is. "Every four ...
For decades, the standard treatment for these potentially ... benralizumab could become the first new therapy approved for eosinophilic exacerbations of asthma and COPD in over 50 years.
A novel way of scanning lungs can demonstrate the impact of treatment on lung function in real-time, allowing experts to ...
For decades, the standard treatment for these potentially ... benralizumab could become the first new therapy approved for eosinophilic exacerbations of asthma and COPD in over 50 years.